Purchase this article with an account.
F.-X. Brousseaud, C. Laurens, B. Dufay Dupar, T. Rodallec, R. Adam, O. Touzeau, J.-P. Nordmann; Long-Term Follow-Up of Intravitreal Bevacizumab for Choroidal Neovascularization in Pathologic Myopia. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2277.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine long-term effects and complications of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia (mCNV).
Retrospective chart review of 11 consecutive patients treated with intravitreal (IVT) bevacizumab (1.25 mg) for subfoveal choroidal neovascularization due to pathological myopia. Best corrected visual acuity (BCVA), ophthalmic examination and OCT were complited at baseline, every month during six months and then every three months. Fluorescein and indocyanin green angiography were performed depending on the clinical and OCT findings. Reinjections were performed if intra or subretinal fluid persisted on OCT or on angiography.
Eleven eyes of 11 patients were included. The mean age was 54.4 years (range 34 to 76 years). Follow-up period after treatment was 13.6 months (range 6 to 21 months).Pre-injection mean BCVA was 0.79 ± 0.22 log MAR. The mean BCVA improved at six months (0.60 ± 0.33, p<0.05) and at one year (0.73 ± 0.22, p<0.05; n=8). At six months, six eyes showed some improvement of at least 2 lines, four eyes remained stable and one eye lost more than one line. The average number of injections was 1.91 injections (range 1 to 3 injections). No injection was done after the first 12 months. Four eyes received only one injection. No intraocular or systemic side effect was observed.
Data from this retrospective study seem to suggest that intravitreal bevacizumab injections is an effective and safe treatment for mCNV. A small number of injection was needed and no eye was injected after one year of follow up.
This PDF is available to Subscribers Only